Radical surgery is associated with significant perioperative mortality in elderly and comorbid populations. emerging data suggest for patients with a clinical complete response after neoadjuvant chemoradiotherapy that a watch-andwait approach may provide equivalent survival and oncological outcomes.
t he standard of care for locally advanced rectal cancer is currently neoadjuvant chemoradiotherapy (CRt) followed by radical surgery (Rs).
1,2 a pathological complete response (pCR), with absence of cancer cells in the resected specimen, however, has been reported in between 15% and 44% of patients.
3,4 subsequently, several studies have demonstrated the safety of adopting a watch-and-wait (WW) strategy after CRt in patients for whom a clinical complete response (cCR) has been achieved where no evidence of residual tumor can be identified. 5, 6 these approaches eliminate perioperative mortality, deliver equivalent oncological outcomes if cCR is maintained, and preserve bowel continuity in patients for whom a stoma is unsuitable or unacceptable. 7 although disease does recur in some patients, limited data suggest that, should this occur, subsequent Rs can be performed with equivalent oncological outcome for patients who were initially treated with Rs. 6, 8 there is now emerging evidence to suggest that long-term oncological outcomes after WW and Rs may be comparable. 9, 10 it now remains to be shown whether WW is costeffective with the intensive surveillance necessary and the costs associated with managing disease recurrence. Consequently, in this study we aimed to compare both the clinical effectiveness and cost-effectiveness of WW and Rs and to investigate and quantify the associated uncertainty. We hypothesized that improved survival, long-term health-related quality of life (hRQol), and reduced surgical costs would result in WW being more cost-effective. We performed alternative analyses to investigate whether these results were sensitive to patient age and comorbidity, hypothesizing that WW would be more cost-effective in elderly and comorbid patients and that associated uncertainty would be reduced in elderly and comorbid patients.
PATIENTS AND METHODS
outcomes in patients with a cCR after neoadjuvant CRt treated with Rs and WW were modeled using a published decision analytical model consisting of a decision tree and markov chain simulation. 10 figure 1 shows the structure of the model. Decision nodes are square, and chance nodes are Schematic representation of our decision-analytic model, consisting of a decision tree and Markov chain simulation to investigate the long-term outcomes associated with the competing interventions. Decision nodes are represented by red boxes, and chance nodes are depicted by blue circles. The decision tree terminates either with the patients dying (in the case of patients who do not survive surgery) or a Markov chain simulation. The transition probabilities for the Markov chain simulation are determined by initial treatment and whether a pathologic complete response was achieved after chemoradiotherapy and are described in Table 1 . circular. the model terminated either with death (when patients did not survive surgery) or a markov simulation. the transition probabilities were determined by initial treatment and whether a pCR was achieved after CRt. Details of all of the interventions that patients underwent in each modeled state are detailed in figures 2 and 3. table 1 shows clinical parameters used to populate the model. these parameters were used in previous work and represent best available estimates. 10 the economic data used to populate the model are listed in table 2. table 3 shows perioperative mortality used to populate the model extracted from the Hospital  episodes statistics database,  13 and table 4 shows baseline mortality data used to populate the model based on united Kingdom office of national statistics life tables. 22 analysis was performed from a third-party payer perspective (united Kingdom national health service (nhs)) according to the national institute for health and Care Excellence guidelines on technology assessment. 28 Costs are reported in US dollars. An exchange rate of $1.4:1 united Kingdom pound sterling (£) was used. 29 the effects of interventions were measured in quality-adjusted life-years (QalYs), a summary measure of survival and utility. incremental costs and effects were calculated for the lifetime of the hypothetical patient cohorts. Costs and effects were discounted at 3.5% per annum according to guidelines on cost-effectiveness analysis. 28 Probabilistic sensitivity analysis was performed to investigate and quantify associated uncertainty. 30 Decision analytical soft- ware (treeage-Pro, treeage, Williamstown, ma) was used to perform the analysis. This study was exempt from institutional review board ethical approval because it is a modeling study and did not require any interface with patients.
Definition of Treatment Strategies, Modeled
Patient Populations, and Outcomes of Interest to be selected for WW management, all of the patients had to undergo a clinical examination after CRT. Only patients deemed to have a cCR by strictly defined criteria 10, 31 were managed with WW, because patients without a cCR are necessarily managed by Rs. a cCR is judged to have occurred in the absence of residual ulceration, stenosis, or mass within the rectum during digital rectal examination and proctoscopy ≥8 weeks after CRt. the only positive finding consistent with a cCR is the presence of whitening of the mucosa or telangiectasia. finally, a diagnosis of cCR necessarily requires normal radiological imaging of the pelvis, particularly the absence of suspicious mesorectal or lateral pelvic nodes and normal Cea levels. 31 Patients with a cCR 31 in our model are either managed by Rs or WW. 5, 6 We assumed that follow-up for patients undergoing surgery was according to national guidelines. 32 Briefly, these recommend a minimum of 2 Cts of the chest, abdomen, and pelvis in the first 3 years. in addition, a surveillance colonoscopy at 1 year is offered after initial treatment. if this is normal, an additional colonoscopy is considered after 5 years. We assumed that, should tumor recurrence occur in either cohort, patients underwent full oncological restaging and salvage surgery where appropriate. Patients in whom salvage surgery was not possible underwent palliative surgery and chemotherapy. Patients with distant metastasis underwent palliative chemotherapy, and a proportion of patients, reflecting actual clinical practice, underwent liver resection. 33 it was assumed that patients received the maximum dose of radiotherapy and so our model did not account for additional costs associated with palliative radiotherapy. Because <1% of patients with colorectal metastasis in the lung undergo resection, we did not account for this in our model (figs. 1-3). 34 in the united states, surveillance after Rs is typically more intensive than in the united Kingdom. Consequently, alternative analysis was performed with follow-up according to the national Comprehensive Cancer network guidelines. 35 Briefly, patients had 3 CTs in the first 2 years followed by twice-yearly Cts until 5 years after resection. Cea sampling was performed 3 times a year in the first 2 years and then twice yearly until 5 years after resection, instead of yearly, as in the base-case analysis. Colonoscopy was performed at years 1 and 3 postresection and every 5 years thereafter. healthcare costs differ radically between healthcare systems. Consequently, an alternative analysis was performed according to national Comprehensive Cancer network Guidelines, with all of the cost parameters double those in base-case analysis and also when only nonsurgical costs where doubled.
to investigate whether the results of our analysis were sensitive to patient age and comorbidities, an analysis was performed for a 60-year-old male cohort (fm60), an 80-year-old male cohort with mild comorbidities ((fm80) Charlson score <3), and an 80-year-old male cohort with significant comorbidities ((cm80) Charlson score ≥3). The Charlson Comorbidity Index is an established tool to predict mortality for a patient who may have a range of comorbid conditions. 36 these cohorts were selected to represent a spread of different prognostic categories encountered in colorectal practice.
Model Parameters
Postoperative mortality in the first 90 days for each demographic cohort was obtained from the hospital episodes See Transition probabilities were described by β distributions based on the listed expected value and range. cCR = complete clinical response; pCR = complete pathological response; pPR = partial pathological response; CRT = chemoradiotherapy.
statistics database, a national database that describes the care provided to patients in nhs hospitals (tables 1 and 3). 13 hospital episodes statistics data are widely used for nhs quality assurance by government agencies and in the academic literature. 15 Baseline mortality estimates were extracted from United Kingdom Office of National Statistics life tables (table 4) . 16 estimates of other clinical parameters used to populate the model were extracted from published literature. 3, 5, 8, [10] [11] [12] [14] [15] [16] [17] [18] [19] [20] [21] the rationale for using these estimates has been discussed previously. 10 there is a paucity of studies comparing the hRQol of patients after radiotherapy and surgery for the primary management of rectal cancer. Consequently, estimates of hRQol after CRt without surgery came from the prostate cancer literature. 23 estimates of the utility values for other health states were based on data from the Dutch Total Mesorectal Excision study 24 and cost-utility analysis of the management of recurrent rectal cancer. 25 finally, estimates of the costs associated with treatment were based on nhs reference costs (2014-2015; table 2).
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Sensitivity Analysis
Deterministic sensitivity analysis was performed to investigate the sensitivity of the study to assumptions made about the value of individual model parameters. each model parameter was varied with plausible ranges (tables 1 and 2). to estimate the combined effect of uncertainty associated with all of the model parameters, a probabilistic sensitivity analysis was performed using a monte Carlo simulation. Briefly, all of the parameters, including transition probabilities, were randomly sampled from assigned distributions (tables 1 and 2). it was assumed that parameters were independent, that is, not correlated with each other. the model was then run to simulate a virtual cohort of 1000 matched patients using these sampled probabilities for each intervention. all of the model parameters were then resampled, and the model was then run again to generate data for an additional virtual cohort of 1000 patients. this process was repeated until data had been generated for 1000 matched virtual cohorts of 1000 patients. this allowed QalY payoffs and costs to be estimated for both treatment strategies. Crucially, however, it also allowed for estimates of the uncertainty associated with these outcomes to be calculated. Because cost parameters may by closely correlated, it is possible that the assumption that all of the model parameters are not correlated may overestimate the uncertainty. Consequently, alternative analysis was performed in which all of the cost parameters were assumed to be perfectly correlated.
RESULTS
in all of the modeled patient cohorts, WW could be said to have dominated Rs because it was both less costly and more effective. in the fm60 cohort, WW was less costly by $11,332.35 ((£8094.54) (95% Ci, -$668.50 (-£477.50) to $23,970.20 (-£17,121.57))) and more effective by 0.63 QalYs (95% Ci, -2.48-3.65 QalYs). in the fm80 cohort, WW was less costly by $8783.93 ((£6274.24) (95% Ci, -$2504.26 (-£1788.76) to $21,900.66 (£15,643.33))) and more effective by 0.56 QalYs (95% Ci, -0.52-1.59 QalYs). Deterministic Sensitivity Analysis the results of deterministic sensitivity analysis at a willingness-to-pay/cost-effectiveness threshold (Cet) of $50,000/QalY is shown in figure 4 . each panel has the plausible ranges for a variable plotted on each axis. The boundary between the shaded areas represents the tipping point of the model at which there is equipoise. the area shaded blue indicates values at which WW is cost-effective, whereas the red indicates that Rs is cost-effective. the results of our model were sensitive to relative recurrence rates for patients with a pathologic complete response after WW and Rs. this had a significant effect on the relative efficacy and hence cost-effectiveness of WW and Rs in all of the demographic cohorts (figs. 4a-C). interestingly, the results of the model were not particularly sensitive to variations in baseline mortality and operative mortality, in any demographic cohort, within plausible ranges (figs. 4D-f), nor were the results sensitive to individual cost parameters. sensitivity analysis suggested that the model was more sensitive to the degree to which hRQol was reduced by Rs (figs. 4G-i), and the model became sensitive to perioperative mortality when the hRQol benefit of WW was reduced (Figs. 4J-L).
Probabilistic Sensitivity Analysis the results of probabilistic sensitivity analysis are shown in figs. 5 and 6. at a Cet of $50,000/QalY, WW is most costeffective in all of the modeled cohorts; however, as patient age and comorbidities increase, uncertainty associated with the results of our model decrease. the cost-effectiveness acceptability curve is a method for summarizing information on uncertainty in cost-effectiveness. the cost-effectiveness acceptability curve identifies the probability that the intervention is cost-effective compared with the alternative based on the data provided for a given Cet. 30 in the fm60 cohort, WW was most cost-effective in 69.6% of model iterations (table 5 and figs. 5a and 6); this increased to 83.5% in the fm80 cohort (Table 5 and Figs. 5B and 6) and 89.2% in the cm80 cohort (table 5 and figs. 5C and 6) at a Cet of $50,000/QalY. at $28,000/QalY (£20,000/QalY), the fm60 cohort WW was most cost-effective in 74.0% (table 5 and fig. 6 ) of model iterations; this increased to 85.0% (table 5 and fig. 6 ) in the fm80 cohort and 90.1% in the cm80 cohort (table 5 and fig. 6 ).
When cost parameters are correlated, the relative efficacy of WW and Rs is not significantly different (table 5) . As expected, the uncertainty associated with these findings was reduced when cost parameters were correlated. the fm60 cohort WW was most cost-effective in 71.6% of model iterations; this increased to 83.7% in the fm80 cohort and 90.8% in the cm80 cohort at a Cet of $50,000/ QalY. at $28,000/QalY (£20,000/QalY), the fm60 co- 
DISCUSSION
this study, to the best of our knowledge, represents the first economic analysis in the literature comparing the lifetime cost-effectiveness of Rs and WW in patients with a cCR after CRt. the results of our model suggest that intensive follow-up associated with WW, and the additional morbidity and mortality associated with managing recurrence in patients with a pathologic complete response who are managed with a WW approach, are outweighed by the cost of Rs and the morbidity and mortality associated with Rs. in all of the demographic cohorts, WW dominates Rs, being less costly and more effective. as age QALY = quality-adjusted life-year; fm60 = 60-year-old male cohort; fm80 = 80-year-old male cohort with mild comorbidities; cm80 = 60-year-old male cohort with significant comorbidities; NCCN = National Comprehensive Cancer Network; CET = cost-effectiveness threshold.
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Operative mortality O perative mortality O perative mortality Utility after surgery U tility after surgery U tility after surgery and patient comorbidities increase, uncertainty associated with these findings decreases. these findings were maintained when alternative analysis was performed according to national Comprehensive Cancer network follow-up protocols, when healthcare costs were grossly inflated, and when follow-up costs were inflated relative to the costs of surgery. although analysis was not performed according to a societal perspective, 37 these results suggest that our findings are transferable beyond a united Kingdom nhs context. Previous work that we have undertaken suggests that WW offers at worst comparable outcomes to Rs in terms of absolute survival and disease-free survival. 10 this is increasingly supported by emerging clinical data. 9 this study suggests that not only is WW clinically effective, it is also cost-effective. these findings have significant implications for clinical practice. there is now compelling evidence to conduct randomized studies to investigate the relative efficacy of WW and Rs, in particular, because deterministic sensitivity analysis suggests that our findings were sensitive to assumptions about the relative recurrence rate of patients with pCR who underwent Rs and WW.
it is also important to define which patient populations would derive the most benefit from each treatment modality, in particular, to define which patient characteristics or biomarkers may predict pCR. finally, research continues to improve the pCR rate of CRT, for example by the addition of contact x-ray brachytherapy boost.
all studies based on statistical and decision analytical models are necessarily simplifications of complex clinical scenarios. For example, in our study it was assumed that all of the patients who had recurrence would undergo salvage surgery when appropriate and palliative chemotherapy when required. this, however, is likely to bias the analysis in favor of Rs, because the recurrence rate is higher in the WW cohort and consequently it is possible that the costs may be overestimated. similarly, our model did not include transition probabilities for the development of distant metastasis after local recurrence because of a paucity of data to populate the model. this assumption affects few patients. however, because mortality rates used in the model for patients with local recurrence included mortality from all causes, including metastatic disease in patients who subsequently developed metastases, and all of the patients with local recurrence were assumed to have chemotherapy, this assumption may have further biased the analysis in favor of Rs. furthermore, our analysis may have also been biased in favor of Rs, because surgical costs may not have been fully captured. For example, we did not account for the long-term costs and complications of stoma care and skilled nursing facilities. analysis was not performed for women. although female patients may have lower baseline mortality and operative mortality, 38 sensitivity analysis did not suggest that the results of analysis were sensitive to these model parameters (fig. 4) .
all of the models are vulnerable to uncertainty associated with model parameters, and consequently we have endeavored to populate our model with the most relevant and robust estimates and to fully quantify uncertainty associated with these model parameters. nevertheless, our model is limited, because much of the data come from selected specialized centers in which significant expertise has been developed in organ-preserving strategies, and it remains to be shown whether this expertise can be effectively disseminated. furthermore, the paucity of hRQol data in this field necessitating the use of data from different populations, with different diseases, measured using different methodology is a significant limitation. [23] [24] [25] We suggest that this should be a focus of future clinical trials in this area. Given the uncertainty associated with these parameters, wide Cis were used in sensitivity analysis. Deterministic sensitivity analysis suggests that the results were only changed by the relative use of Rs and conservative management in the unlikely scenario that Rs conferred better hRQol than organ-conserving strategies (figs. 4G-i). Because all decision analytical models require simplifying assumptions about clinical pathways and are vulnerable to parameter uncertainty, the results of these studies must be interpreted with caution. some reassurance, however, can be drawn from the fact that estimates of the relative clinical effectiveness of WW and Rs made using this model and clinical studies are congruent.
9,10 furthermore, every effort was made to perform exhaustive sensitivity analysis and to avoid bias toward WW to ensure that the results of our study were robust.
CONCLUSION
this study strongly suggests that WW is cost-effective compared with Rs. in conjunction with emerging evidence on the clinical effectiveness of WW compared with RS, this study suggests that randomized evidence should be sought to define the role of WW in managing patients with a cCR after CRt for rectal cancer.
